OTCMKTS:ALTA - Alterola Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.99 0.00 (0.00 %)
(As of 04/21/2019 04:00 PM ET)
Previous Close$1.99
Today's Range$1.99 - $1.99
52-Week Range$0.20 - $3.99
Volume105 shs
Average Volume412 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Alterola Biotech, Inc., a development stage company, focuses on the development of nutrition and health chewing gums with natural based ingredients in the United States. Its products under development include appetite suppressors, cholesterol suppressors, antioxidant gums, motion sickness suppressors, and vitamin gums. The company was formerly known as Jedediah Resources Corp. and changed its name to Alterola Biotech, Inc. in July 2010. Alterola Biotech, Inc. was founded in 2008 and is based in Walnut, California. Alterola Biotech, Inc. is a subsidiary of London Pharma Holdings Limited.

Receive ALTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Conglomerates
Current SymbolOTCMKTS:ALTA



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Alterola Biotech (OTCMKTS:ALTA) Frequently Asked Questions

What is Alterola Biotech's stock symbol?

Alterola Biotech trades on the OTCMKTS under the ticker symbol "ALTA."

Has Alterola Biotech been receiving favorable news coverage?

News articles about ALTA stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alterola Biotech earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Alterola Biotech's key competitors?

What other stocks do shareholders of Alterola Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alterola Biotech investors own include Nucor (NUE), NVIDIA (NVDA), Adobe (ADBE), Amgen (AMGN), Biogen (BIIB), Costco Wholesale (COST), Roku (ROKU), AbbVie (ABBV), AdvanSix (ASIX) and Alibaba Group (BABA).

Who are Alterola Biotech's key executives?

Alterola Biotech's management team includes the folowing people:
  • Mr. Rene Lauritsen, Chief Operating Officer (Age 45)
  • Mr. Peter Maddocks, CEO, Pres, CFO, Principal Accounting Officer & Director (Age 60)

How do I buy shares of Alterola Biotech?

Shares of ALTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alterola Biotech's stock price today?

One share of ALTA stock can currently be purchased for approximately $1.99.

What is Alterola Biotech's official website?

The official website for Alterola Biotech is http://www.alterolabiotech.com/.

How can I contact Alterola Biotech?

Alterola Biotech's mailing address is 228 Hamilton Ave Fl 3, PALO ALTO, CA 94301-2583, United States. The company can be reached via phone at +1-458-8429181.

MarketBeat Community Rating for Alterola Biotech (OTCMKTS ALTA)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  65
MarketBeat's community ratings are surveys of what our community members think about Alterola Biotech and other stocks. Vote "Outperform" if you believe ALTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel